Seattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $129.6 million versus the consensus estimate of $116.24 million.

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.